Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Front Med (Lausanne) ; 7: 604182, 2020.
Article in English | MEDLINE | ID: mdl-33415118

ABSTRACT

The unprecedented surge of nephrology inpatients needing kidney replacement therapy placed hospital systems under extreme stress during the COVID-19 pandemic. In this article, we describe the formation of a cross campus "New-York Presbyterian COVID-19 Kidney Replacement Therapy Task Force" with intercampus physician, nursing, and supply chain representation. We describe several strategies including the development of novel dashboards to track supply/demand of resources, urgent start peritoneal dialysis, in-house preparation of kidney replacement fluid, the use of unconventional personnel resources to ensure the safe and continued provision of kidney replacement therapy in the face of the unanticipated surge. These approaches facilitated equitable sharing of resources across a complex healthcare-system and allowed for the rapid implementation of standardized protocols at each hospital.

2.
Am J Ther ; 23(4): e1064-7, 2016.
Article in English | MEDLINE | ID: mdl-26035034

ABSTRACT

The issue of vancomycin-induced acute kidney injury (AKI) has resurged with the use of intravenous vancomycin as a first-line antibiotic, often for prolonged periods of time for the management of serious methicillin-resistant Staphylococcus aureus infections, and with a higher recommended trough level (15-20 µg/mL). We have observed 3 patients on intravenous vancomycin who developed very high trough levels (>40 µg/mL) and severe (stage 3) AKI. Those 3 patients underwent kidney biopsy for unresolving AKI, which revealed findings compatible with acute tubular necrosis. The first patient initially developed asymptomatic acute interstitial nephritis because of a concomitant antibiotic that caused worsening of kidney function, and the dose of vancomycin was not properly adjusted while staying at the nursing home. The second was an emaciated patient (BMI, 14) whose serum creatinine level was a deceptive marker of kidney function for the proper dosing of vancomycin, resulting in a toxic level. The third patient developed vancomycin-related AKI on an initially high therapeutic level, which then contributed to further rising in vancomycin level and subsequently causing severe AKI. One patient required hemodialysis, but all 3 patients ultimately recovered their kidney function significantly. A regular monitoring (preferably twice weekly) of serum creatinine and vancomycin trough level is advisable to minimize vancomycin-associated AKI, primarily acute tubular necrosis, for patients requiring prolonged administration of vancomycin (>2 weeks) on the currently recommended higher therapeutic trough levels (>15 µg/mL).


Subject(s)
Acute Kidney Injury/chemically induced , Anti-Bacterial Agents/adverse effects , Methicillin-Resistant Staphylococcus aureus , Staphylococcal Infections/drug therapy , Vancomycin/adverse effects , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/pharmacokinetics , Creatinine/blood , Dose-Response Relationship, Drug , Drug Monitoring , Female , Humans , Kidney Tubular Necrosis, Acute/chemically induced , Male , Middle Aged , Nephritis, Interstitial/chemically induced , Vancomycin/administration & dosage , Vancomycin/pharmacokinetics
3.
Adv Perit Dial ; 32: 19-21, 2016.
Article in English | MEDLINE | ID: mdl-28988585

ABSTRACT

Encapsulating peritoneal sclerosis (EPS) is an infrequent but serious complication that is observed mostly in patients on long-term peritoneal dialysis (PD). However it can occur after short-term PD, in association with "second hit" risk factors such as peritonitis, acute cessation of PD, or kidney transplantation with the use of calcineurin inhibitors.In our case, a young woman with second-hit risk factors presented with clinical and abdominal computed tomography findings consistent with EPS after short-term PD. She was treated conservatively with nutritional support and was discharged in improved and stable clinical status.In general, the diagnosis of EPS requires clinical findings of bowel obstruction combined with typical computed tomography imaging features. However, the clinical manifestations can be very vague, and the diagnosis is often unclear. A recent study categorized EPS into 4 clinical stages, from pre-EPS to chronic ileus, with associated management from conservative treatment to surgical intervention.In association with second-hit risk factors, EPS can occur after short-term PD. Severity is variable, and the outcome is often devastating. Timely recognition and expert management of EPS can change the outcome very favorably.


Subject(s)
Kidney Failure, Chronic/therapy , Peritoneal Dialysis/adverse effects , Peritoneal Fibrosis/etiology , Female , Graft Rejection , Humans , Kidney Transplantation , Peritoneal Fibrosis/diagnostic imaging , Peritonitis , Renal Dialysis , Time Factors , Tomography, X-Ray Computed , Young Adult
4.
Hemodial Int ; 17 Suppl 1: S33-6, 2013 Oct.
Article in English | MEDLINE | ID: mdl-24134329

ABSTRACT

Calciphylaxis, also called calcific uremic arteriolopathy is a dreadful, life-threatening ischemic vasculopathy, primarily involving skin and subcutaneous tissue, mostly on patients with end-stage kidney disease. Calciphylaxis is a well-described, but still a poorly understood disorder of mineral metabolism. Its occurrence is rare, but increasingly reported. We describe a 62-year-old obese lady on hemodialysis for end-stage kidney disease due to type 2 diabetes, who developed two episodes of calciphylactic skin lesions during the 3 years observation. The healing of lesions in the first episode was prompted by a subtotal parathyroidectomy for severe secondary hyperparathyroidism. However, the resumption of oral calcium and vitamin D analog for the parathyroidectomy-related hypocalcemia induced another occurrence of widespread calciphylactic skin lesions in areas of great adiposity. The typical regimen of IV sodium thiosulfate brought a successful outcome to the second episode. Now, growing numbers of successful treatment for calciphylaxis are reported with more specific therapies and a clear understanding of the pathogenetic mechanism is in sight.


Subject(s)
Calciphylaxis/surgery , Parathyroidectomy/methods , Skin Diseases/surgery , Calciphylaxis/complications , Calciphylaxis/pathology , Female , Humans , Hyperparathyroidism/complications , Hyperparathyroidism/surgery , Kidney Failure, Chronic/complications , Kidney Failure, Chronic/therapy , Middle Aged , Renal Dialysis , Skin Diseases/complications , Skin Diseases/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...